{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T14:00:54Z","timestamp":1790776854326,"version":"4.1.0"},"reference-count":44,"publisher":"Harborside Press, LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,30]]},"abstract":"<jats:p>\n                    <jats:bold>Background:<\/jats:bold>\n                    Optimizing surveillance for the growing population of breast cancer survivors remains a challenge. Although screening guidelines for initial breast cancer are well established, current surveillance guidelines recommending routine provider examinations rely heavily on expert consensus rather than real-world data. Limited evidence exists on how second breast cancer events, including recurrences and contralateral new primary breast cancer, are actually detected in practice.\n                    <jats:bold>Methods:<\/jats:bold>\n                    We analyzed data from the Pathways Study, a prospective cohort of women diagnosed with stage I\u2013III breast cancer at Kaiser Permanente Northern California between 2005 and 2013 and followed through 2021. We assessed the timing, outcomes, and detection modality of second events, categorized as patient-reported symptoms, surveillance mammogram, provider examination, incidental finding, or ancillary testing.\n                    <jats:bold>Results:<\/jats:bold>\n                    Of 4,417 eligible women, 792 (17.9%) experienced a second event: 577 (13.1%) had a recurrence and 215 (4.9%) developed a contralateral new primary. Most recurrences were metastatic (70.0%) and symptom-detected (78.0%), with only 9.9% found via surveillance mammogram and 5.0% by provider examination. In contrast, 82.8% of contralateral new primaries were detected via mammogram, with only 0.5% found on provider examination. Recurrences clustered within 5 years postdiagnosis and were associated with poor survival, whereas contralateral primaries occurred steadily over time with more favorable outcomes.\n                    <jats:bold>Conclusions:<\/jats:bold>\n                    In this large, diverse cohort with high access to survivorship care, routine provider examinations rarely detected second breast cancer events. Detection patterns differed by event type, with recurrences typically early, metastatic, and symptom-detected, whereas contralateral new primaries were found via imaging across the follow-up period. These findings support consideration of more individualized, risk-adapted surveillance strategies that emphasize symptom awareness, patient education, and appropriate use of imaging, rather than uniform examination-based approaches. Further research is needed to evaluate emerging tools, such as circulating tumor DNA and artificial intelligence, to improve the timely detection of second events and survivorship outcomes.\n                  <\/jats:p>","DOI":"10.6004\/jnccn.2026.7044","type":"journal-article","created":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T13:32:51Z","timestamp":1790775171000},"page":"1-8","source":"Crossref","is-referenced-by-count":0,"title":["Detection Patterns of Breast Cancer Recurrence and Contralateral New Primaries in a Large Integrated Health System"],"prefix":"10.6004","author":[{"given":"Ali M.","family":"Duffens","sequence":"first","affiliation":[{"name":"Kaiser Permanente Northern California, San Francisco Medical Center, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecile A.","family":"Laurent","sequence":"additional","affiliation":[{"name":"Division of Research, Kaiser Permanente Northern California, Pleasanton, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isaac J.","family":"Ergas","sequence":"additional","affiliation":[{"name":"Division of Research, Kaiser Permanente Northern California, Pleasanton, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janise M.","family":"Roh","sequence":"additional","affiliation":[{"name":"Division of Research, Kaiser Permanente Northern California, Pleasanton, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vignesh A.","family":"Arasu","sequence":"additional","affiliation":[{"name":"Division of Research, Kaiser Permanente Northern California, Pleasanton, CA"},{"name":"Department of Radiology, Kaiser Permanente Northern California, Vallejo Medical Center, Vallejo, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence H.","family":"Kushi","sequence":"additional","affiliation":[{"name":"Division of Research, Kaiser Permanente Northern California, Pleasanton, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond","family":"Liu","sequence":"additional","affiliation":[{"name":"Division of Research, Kaiser Permanente Northern California, Pleasanton, CA"},{"name":"Department of Hematology and Oncology, Kaiser Permanente Northern California, San Francisco Medical Center, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4047","reference":[{"key":"B1","series-title":"CA Cancer J Clin","first-page":"477","article-title":"Breast cancer statistics 2024","volume":"74","author":"Giaquinto AN","year":"2024","unstructured":"Giaquinto AN, Sung H, Newman LA,  Breast cancer statistics 2024. CA Cancer J Clin 2024;74:477\u2013495."},{"key":"B2","article-title":"Cancer stat facts: female breast cancer","unstructured":"National Cancer Institute. Cancer stat facts: female breast cancer. Accessed June 2, 2026. Available at: https:\/\/seer.cancer.gov\/statfacts\/html\/breast.html"},{"key":"B3","series-title":"Cancer","first-page":"2379","article-title":"Breast cancer early detection: a phased approach to implementation","volume":"126(","author":"Ginsburg O","year":"2020","unstructured":"Ginsburg O, Yip CH, Brooks A,  Breast cancer early detection: a phased approach to implementation. Cancer 2020;126(Suppl 10):2379\u20132393."},{"key":"B4","series-title":"JAMA","first-page":"233","article-title":"Analysis of breast cancer mortality in the US\u20131975 to 2019","volume":"331","author":"Caswell-Jin JL","year":"2024","unstructured":"Caswell-Jin JL, Sun LP, Munoz D,  Analysis of breast cancer mortality in the US\u20131975 to 2019. JAMA 2024;331:233\u2013241."},{"key":"B5","series-title":"J Clin Oncol","first-page":"927","article-title":"Annual hazard rates of recurrence for breast cancer during 24 years of follow-up: results from the International Breast Cancer Study Group trials I to V","volume":"34","author":"Colleoni M","year":"2016","unstructured":"Colleoni M, Sun Z, Price KN,  Annual hazard rates of recurrence for breast cancer during 24 years of follow-up: results from the International Breast Cancer Study Group trials I to V. J Clin Oncol 2016;34:927\u2013935."},{"key":"B6","series-title":"N Engl J Med","first-page":"1836","article-title":"EBCTCG 20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years","volume":"377","author":"Pan H","year":"2017","unstructured":"Pan H, Gray R, Braybrooke J,  EBCTCG 20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years. N Engl J Med 2017;377:1836\u20131846."},{"key":"B7","series-title":"Br J Cancer","first-page":"601","article-title":"The risk of contralateral breast cancer: a SEER-based analysis","volume":"125","author":"Giannakeas V","year":"2021","unstructured":"Giannakeas V, Lim DW, Narod SA. The risk of contralateral breast cancer: a SEER-based analysis. Br J Cancer 2021;125:601\u2013610."},{"key":"B8","series-title":"Breast Cancer Res","first-page":"24","article-title":"Risk of contralateral breast cancer according to first breast cancer characteristics among women in the USA, 1992\u20132016","volume":"23","author":"Ramin C","year":"2021","unstructured":"Ramin C, Withrow DR, Davis Lynn BC,  Risk of contralateral breast cancer according to first breast cancer characteristics among women in the USA, 1992\u20132016. Breast Cancer Res 2021;23:24."},{"key":"B9","series-title":"Breast Cancer Res Treat","first-page":"111","article-title":"Clinical breast exam contribution to breast cancer diagnosis in BRCA mutation carriers vs. average to intermediate risk women","volume":"207","author":"Menes TS","year":"2024","unstructured":"Menes TS, Zippel D, Sklair-Levy M,  Clinical breast exam contribution to breast cancer diagnosis in BRCA mutation carriers vs. average to intermediate risk women. Breast Cancer Res Treat 2024;207:111\u2013118."},{"key":"B10","series-title":"Ann Surg Oncol","first-page":"7524","article-title":"Routine clinical breast examination is a low-yield practice among women at high risk of breast cancer","volume":"31","author":"Hua T","year":"2024","unstructured":"Hua T, Mendoza S, McCririe-Balcom M,  Routine clinical breast examination is a low-yield practice among women at high risk of breast cancer. Ann Surg Oncol 2024;31:7524\u20137531."},{"key":"B11","series-title":"Cancer Causes Control","first-page":"1065","article-title":"The Pathways Study: a prospective study of breast cancer survivorship within Kaiser Permanente Northern California","volume":"19","author":"Kwan ML","year":"2008","unstructured":"Kwan ML, Ambrosone CB, Lee MM,  The Pathways Study: a prospective study of breast cancer survivorship within Kaiser Permanente Northern California. Cancer Causes Control 2008;19:1065\u20131076."},{"key":"B12","series-title":"BMC Cancer","first-page":"688","article-title":"Representativeness of breast cancer cases in an integrated health care delivery system","volume":"15","author":"Gomez SL","year":"2015","unstructured":"Gomez SL, Shariff-Marco S, Von Behren J,  Representativeness of breast cancer cases in an integrated health care delivery system. BMC Cancer 2015;15:688."},{"key":"B13","series-title":"Eur Radiol","first-page":"2484","article-title":"Surveillance mammography for detecting ipsilateral breast tumour recurrence and metachronous contralateral breast cancer: a systematic review","volume":"21","author":"Robertson C","year":"2011","unstructured":"Robertson C, Ragupathy SK, Boachie C,  Surveillance mammography for detecting ipsilateral breast tumour recurrence and metachronous contralateral breast cancer: a systematic review. Eur Radiol 2011;21:2484\u20132491."},{"key":"B14","series-title":"Breast","first-page":"274","article-title":"Regularly scheduled physical examinations and the detection of breast cancer recurrences","volume":"69","author":"Beltran-Bless AA","year":"2023","unstructured":"Beltran-Bless AA, Alshamsan B, Alzahrani MJ,  Regularly scheduled physical examinations and the detection of breast cancer recurrences. Breast 2023;69:274\u2013280."},{"key":"B15","series-title":"J Natl Cancer Inst","first-page":"1371","article-title":"Surveillance imaging vs symptomatic recurrence detection and survival in stage II-III breast cancer (AFT-01)","volume":"114","author":"Schumacher JR","year":"2022","unstructured":"Schumacher JR, Neuman HB, Yu M,  Surveillance imaging vs symptomatic recurrence detection and survival in stage II-III breast cancer (AFT-01). J Natl Cancer Inst 2022;114:1371\u20131379."},{"key":"B16","series-title":"Breast Cancer Res Treat","first-page":"239","article-title":"Beyond the 5-year mark: adherence to and continuation of extended adjuvant endocrine therapy in non-metastatic breast cancer patients","volume":"214","author":"Wei J","year":"2025","unstructured":"Wei J, Aller A, Zhu S,  Beyond the 5-year mark: adherence to and continuation of extended adjuvant endocrine therapy in non-metastatic breast cancer patients. Breast Cancer Res Treat 2025;214:239\u2013246."},{"key":"B17","series-title":"J Natl Cancer Inst","first-page":"391","article-title":"The incidence of breast cancer recurrence 10-32 years after primary diagnosis","volume":"114","author":"Pedersen RN","year":"2022","unstructured":"Pedersen RN, Esen B\u00d6, Mellemkj\u00e6r L,  The incidence of breast cancer recurrence 10-32 years after primary diagnosis. J Natl Cancer Inst 2022;114:391\u2013399."},{"key":"B18","series-title":"Breast Cancer Res Treat","first-page":"709","article-title":"Patterns and predictors of first and subsequent recurrence in women with early breast cancer","volume":"165","author":"Geurts YM","year":"2017","unstructured":"Geurts YM, Witteveen A, Bretveld R,  Patterns and predictors of first and subsequent recurrence in women with early breast cancer. Breast Cancer Res Treat 2017;165:709\u2013720."},{"key":"B19","series-title":"Breast Cancer Res Treat","first-page":"459","article-title":"Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review","volume":"134","author":"Murphy CC","year":"2012","unstructured":"Murphy CC, Bartholomew LK, Carpentier MY,  Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review. Breast Cancer Res Treat 2012;134:459\u2013478."},{"key":"B20","series-title":"Oncology","first-page":"189","article-title":"Does guideline-adherent therapy improve the outcome for early-onset breast cancer patients?","volume":"78","author":"Varga D","year":"2010","unstructured":"Varga D, Wischnewsky M, Atassi Z,  Does guideline-adherent therapy improve the outcome for early-onset breast cancer patients? Oncology 2010;78:189\u2013195."},{"key":"B21","series-title":"Breast Cancer Res Treat","first-page":"405","article-title":"Breast cancer survival, survival disparities, and guideline-based treatment","volume":"170","author":"Hill DA","year":"2018","unstructured":"Hill DA, Friend S, Lomo L,  Breast cancer survival, survival disparities, and guideline-based treatment. Breast Cancer Res Treat 2018;170:405\u2013414."},{"key":"B22","series-title":"J Clin Oncol","first-page":"3885","article-title":"Age, breast cancer subtype approximation, and local recurrence after breast-conserving therapy","volume":"29","author":"Arvold ND","year":"2011","unstructured":"Arvold ND, Taghian AG, Niemierko A,  Age, breast cancer subtype approximation, and local recurrence after breast-conserving therapy. J Clin Oncol 2011;29:3885\u20133891."},{"key":"B23","series-title":"Breast Cancer Res Treat","first-page":"863","article-title":"Diagnosis of second breast cancer events after initial diagnosis of early stage breast cancer","volume":"124","author":"Buist DS","year":"2010","unstructured":"Buist DS, Abraham LA, Barlow WE,  Diagnosis of second breast cancer events after initial diagnosis of early stage breast cancer. Breast Cancer Res Treat 2010;124:863\u2013873."},{"key":"B24","series-title":"J Clin Oncol","first-page":"3083","article-title":"Patterns of recurrence and outcome according to breast cancer subtypes in lymph node-negative disease: results from International Breast Cancer Study Group trials VIII and IX","volume":"31","author":"Metzger-Filho O","year":"2013","unstructured":"Metzger-Filho O, Sun Z, Viale G,  Patterns of recurrence and outcome according to breast cancer subtypes in lymph node-negative disease: results from International Breast Cancer Study Group trials VIII and IX. J Clin Oncol 2013;31:3083\u20133090."},{"key":"B25","series-title":"JCO Oncol Pract","first-page":"735","article-title":"Oncology, primary care, and survivorship: time for onco-primary care?","volume":"21","author":"Oeffinger KC","year":"2025","unstructured":"Oeffinger KC, Corbett C, Shah KP, Zullig LL. Oncology, primary care, and survivorship: time for onco-primary care? JCO Oncol Pract 2025;21:735\u2013738."},{"key":"B26","article-title":"NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. Version 3.2024","author":"Gradishar WJ","unstructured":"Gradishar WJ, Moran MS, Abraham J,  NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. Version 3.2024. Accessed June 2, 2026. To view the most recent version, visit https:\/\/www.nccn.org"},{"key":"B27","series-title":"BMC Cancer","first-page":"238","article-title":"Options for early breast cancer follow-up in primary and secondary care - a systematic review","volume":"12","author":"Taggart F","year":"2012","unstructured":"Taggart F, Donnelly P, Dunn J. Options for early breast cancer follow-up in primary and secondary care - a systematic review. BMC Cancer 2012;12:238."},{"key":"B28","series-title":"CA Cancer J Clin","first-page":"327","article-title":"Clinical breast examination: practical recommendations for optimizing performance and reporting","volume":"54","author":"Saslow D","year":"2004","unstructured":"Saslow D, Hannan J, Osuch J,  Clinical breast examination: practical recommendations for optimizing performance and reporting. CA Cancer J Clin 2004;54:327\u2013344."},{"key":"B29","series-title":"CA Cancer J Clin","first-page":"345","article-title":"Performance and reporting of clinical breast examination: a review of the literature","volume":"54","author":"McDonald S","year":"2004","unstructured":"McDonald S, Saslow D, Alciati MH. Performance and reporting of clinical breast examination: a review of the literature. CA Cancer J Clin 2004;54:345\u2013361."},{"key":"B30","series-title":"J Clin Oncol","first-page":"2038","article-title":"Nurse-led individualized follow-up versus regular physician-led visits after early breast cancer (MyHealth): a phase III randomized, controlled trial","volume":"42","author":"Saltb\u00e6k L","year":"2024","unstructured":"Saltb\u00e6k L, Bidstrup PE, Karlsen RV,  Nurse-led individualized follow-up versus regular physician-led visits after early breast cancer (MyHealth): a phase III randomized, controlled trial. J Clin Oncol 2024;42:2038\u20132049."},{"key":"B31","series-title":"Br J Cancer","first-page":"1625","article-title":"Alternative methods of follow up in breast cancer: a systematic review of the literature","volume":"96","author":"Montgomery DA","year":"2007","unstructured":"Montgomery DA, Krupa K, Cooke TG. Alternative methods of follow up in breast cancer: a systematic review of the literature. Br J Cancer 2007;96:1625\u20131632."},{"key":"B32","series-title":"Cochrane Database Syst Rev","first-page":"CD001768","article-title":"Follow-up strategies for women treated for early breast cancer","volume":"2005","author":"Rojas MP","year":"2005","unstructured":"Rojas MP, Telaro E, Russo A,  Follow-up strategies for women treated for early breast cancer. Cochrane Database Syst Rev 2005;2005:CD001768."},{"key":"B33","series-title":"Cochrane Database Syst Rev","first-page":"CD001768","article-title":"Follow-up strategies for women treated for early breast cancer","volume":"2016","author":"Moschetti I","year":"2016","unstructured":"Moschetti I, Cinquini M, Lambertini M,  Follow-up strategies for women treated for early breast cancer. Cochrane Database Syst Rev 2016;2016:CD001768."},{"key":"B34","series-title":"Cancer Treat Rev","first-page":"102434","article-title":"Rethinking breast cancer follow-up based on individual risk and recurrence management","volume":"109","author":"De Rose F","year":"2022","unstructured":"De Rose F, Meduri B, De Santis MC,  Rethinking breast cancer follow-up based on individual risk and recurrence management. Cancer Treat Rev 2022;109:102434."},{"key":"B35","series-title":"J Cancer","first-page":"281","article-title":"Current approaches and challenges in early detection of breast cancer recurrence","volume":"5","author":"Schneble EJ","year":"2014","unstructured":"Schneble EJ, Graham LJ, Shupe MP,  Current approaches and challenges in early detection of breast cancer recurrence. J Cancer 2014;5:281\u2013290."},{"key":"B36","series-title":"Breast Cancer Res Treat","first-page":"16","article-title":"Prognostic significance of circulating tumor DNA in early breast cancer: a systematic review and meta-analysis","volume":"216","author":"Sisca L","year":"2026","unstructured":"Sisca L, Polito MG, Silletta M,  Prognostic significance of circulating tumor DNA in early breast cancer: a systematic review and meta-analysis. Breast Cancer Res Treat 2026;216:16."},{"key":"B37","series-title":"Front Oncol","first-page":"1735752","article-title":"Accuracy of ctDNA-based minimal residual disease detection in predicting postoperative recurrence of breast cancer: a meta-analysis","volume":"16","author":"You H","year":"2026","unstructured":"You H, He J, Tian T. Accuracy of ctDNA-based minimal residual disease detection in predicting postoperative recurrence of breast cancer: a meta-analysis. Front Oncol 2026;16:1735752."},{"key":"B38","series-title":"Cancer Innov","first-page":"e159","article-title":"Artificial intelligence and breast cancer management: from data to the clinic","volume":"4","author":"Feng K","year":"2025","unstructured":"Feng K, Yi Z, Xu B. Artificial intelligence and breast cancer management: from data to the clinic. Cancer Innov 2025;4:e159."},{"key":"B39","series-title":"Nat Commun","first-page":"5876","article-title":"Deep learning assessment of metastatic relapse risk from digitized breast cancer histological slides","volume":"16","author":"Garberis I","year":"2025","unstructured":"Garberis I, Gaury V, Saillard C,  Deep learning assessment of metastatic relapse risk from digitized breast cancer histological slides. Nat Commun 2025;16:5876."},{"key":"B40","series-title":"Acta Oncol","first-page":"635","article-title":"Fear of cancer recurrence eight years after early-stage breast cancer \u2013 results from a national survey","volume":"62","author":"Vandraas K","year":"2023","unstructured":"Vandraas K, Reinertsen KV, Smedsland S,  Fear of cancer recurrence eight years after early-stage breast cancer \u2013 results from a national survey. Acta Oncol 2023;62:635\u2013641."},{"key":"B41","series-title":"Psychooncology","first-page":"e70307","article-title":"Factors associated with fear of cancer recurrence in a multiethnic cohort of patients with breast cancer","volume":"34","author":"Jamal A","year":"2025","unstructured":"Jamal A, Zhao F, Freeman JQ,  Factors associated with fear of cancer recurrence in a multiethnic cohort of patients with breast cancer. Psychooncology 2025;34:e70307."},{"key":"B42","series-title":"EClinicalMedicine","first-page":"103599","article-title":"Less is more: inverting the paradigm across the cancer care continuum","volume":"90","author":"Vos JAM","year":"2025","unstructured":"Vos JAM, Barjesteh van Waalwijk van Doorn-Khosrovani S, Westgeest HM. Less is more: inverting the paradigm across the cancer care continuum. EClinicalMedicine 2025;90:103599."},{"key":"B43","series-title":"Cancer Nurs","first-page":"124","article-title":"The integration of emotional, physiologic, and communication responses to medical oncology surveillance appointments during breast cancer survivorship","volume":"40","author":"Clayton MF","year":"2017","unstructured":"Clayton MF, Dingley C, Donaldson G. The integration of emotional, physiologic, and communication responses to medical oncology surveillance appointments during breast cancer survivorship. Cancer Nurs 2017;40:124\u2013134."},{"key":"B44","series-title":"Lancet","first-page":"1537","article-title":"Management of common clinical problems experienced by survivors of cancer","volume":"399","author":"Emery J","year":"2022","unstructured":"Emery J, Butow P, Lai-Kwon J,  Management of common clinical problems experienced by survivors of cancer. Lancet 2022;399:1537\u20131550."}],"container-title":["Journal of the National Comprehensive Cancer Network"],"original-title":[],"link":[{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/aop\/article-10.6004-jnccn.2026.7044\/article-10.6004-jnccn.2026.7044.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/aop\/article-10.6004-jnccn.2026.7044\/article-10.6004-jnccn.2026.7044.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T13:32:51Z","timestamp":1790775171000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/aop\/article-10.6004-jnccn.2026.7044\/article-10.6004-jnccn.2026.7044.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,30]]},"references-count":44,"URL":"https:\/\/doi.org\/10.6004\/jnccn.2026.7044","relation":{},"ISSN":["1540-1405","1540-1413"],"issn-type":[{"value":"1540-1405","type":"print"},{"value":"1540-1413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,30]]}}}